Prime Medicine (PRME) Competitors $1.68 -0.06 (-3.45%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$1.70 +0.02 (+0.89%) As of 05/2/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock PRME vs. RCUS, COLL, AVDL, VIR, AVXL, BCAX, CMRX, CDMO, DAWN, and OCSShould you be buying Prime Medicine stock or one of its competitors? The main competitors of Prime Medicine include Arcus Biosciences (RCUS), Collegium Pharmaceutical (COLL), Avadel Pharmaceuticals (AVDL), Vir Biotechnology (VIR), Anavex Life Sciences (AVXL), Bicara Therapeutics (BCAX), Chimerix (CMRX), Avid Bioservices (CDMO), Day One Biopharmaceuticals (DAWN), and Oculis (OCS). These companies are all part of the "pharmaceutical products" industry. Prime Medicine vs. Arcus Biosciences Collegium Pharmaceutical Avadel Pharmaceuticals Vir Biotechnology Anavex Life Sciences Bicara Therapeutics Chimerix Avid Bioservices Day One Biopharmaceuticals Oculis Prime Medicine (NYSE:PRME) and Arcus Biosciences (NYSE:RCUS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, community ranking, dividends, profitability and analyst recommendations. Do insiders & institutionals believe in PRME or RCUS? 70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are held by institutional investors. 23.5% of Prime Medicine shares are held by insiders. Comparatively, 12.3% of Arcus Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more volatility & risk, PRME or RCUS? Prime Medicine has a beta of 1.88, meaning that its share price is 88% more volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 1.54, meaning that its share price is 54% more volatile than the S&P 500. Does the MarketBeat Community believe in PRME or RCUS? Arcus Biosciences received 169 more outperform votes than Prime Medicine when rated by MarketBeat users. However, 66.67% of users gave Prime Medicine an outperform vote while only 65.45% of users gave Arcus Biosciences an outperform vote. CompanyUnderperformOutperformPrime MedicineOutperform Votes2866.67% Underperform Votes1433.33% Arcus BiosciencesOutperform Votes19765.45% Underperform Votes10434.55% Which has better valuation and earnings, PRME or RCUS? Prime Medicine has higher earnings, but lower revenue than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrime Medicine$2.98M73.87-$198.13M-$1.65-1.02Arcus Biosciences$258M3.72-$307M-$3.10-2.94 Do analysts rate PRME or RCUS? Prime Medicine presently has a consensus target price of $13.38, suggesting a potential upside of 696.13%. Arcus Biosciences has a consensus target price of $28.38, suggesting a potential upside of 211.13%. Given Prime Medicine's stronger consensus rating and higher possible upside, research analysts clearly believe Prime Medicine is more favorable than Arcus Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prime Medicine 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Arcus Biosciences 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is PRME or RCUS more profitable? Prime Medicine has a net margin of 0.00% compared to Arcus Biosciences' net margin of -102.66%. Arcus Biosciences' return on equity of -45.59% beat Prime Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Prime MedicineN/A -107.87% -74.97% Arcus Biosciences -102.66%-45.59%-22.38% Does the media favor PRME or RCUS? In the previous week, Arcus Biosciences had 4 more articles in the media than Prime Medicine. MarketBeat recorded 5 mentions for Arcus Biosciences and 1 mentions for Prime Medicine. Arcus Biosciences' average media sentiment score of 1.39 beat Prime Medicine's score of 0.51 indicating that Arcus Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcus Biosciences 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryPrime Medicine beats Arcus Biosciences on 10 of the 17 factors compared between the two stocks. Get Prime Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for PRME and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRME vs. The Competition Export to ExcelMetricPrime MedicineBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$220.35M$2.97B$5.55B$19.19BDividend YieldN/A1.87%5.09%4.00%P/E Ratio-0.8230.5222.6933.46Price / Sales73.87494.90404.2929.18Price / CashN/A168.6838.1817.52Price / Book1.233.216.794.55Net Income-$198.13M-$72.35M$3.22B$1.02B7 Day Performance-0.59%13.48%3.34%2.26%1 Month Performance4.35%12.33%6.89%2.90%1 Year Performance-69.95%-23.51%16.09%4.63% Prime Medicine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRMEPrime Medicine2.4885 of 5 stars$1.68-3.4%$13.38+696.1%-70.1%$220.35M$2.98M-0.82234RCUSArcus Biosciences2.3894 of 5 stars$8.25-0.6%$28.38+243.9%-41.1%$867.39M$258M-2.62500Upcoming EarningsNews CoverageCOLLCollegium Pharmaceutical3.9808 of 5 stars$26.87+0.3%$43.60+62.3%-26.3%$863.39M$631.45M11.58210Upcoming EarningsNews CoveragePositive NewsAVDLAvadel Pharmaceuticals2.5858 of 5 stars$8.75-0.2%$19.88+127.1%-52.5%$845.50M$169.12M-11.0870Upcoming EarningsNews CoveragePositive NewsGap UpVIRVir Biotechnology2.7032 of 5 stars$6.10-0.3%$33.57+450.4%-32.9%$842.19M$63.71M-1.56580News CoverageAVXLAnavex Life Sciences3.8272 of 5 stars$9.58+1.7%$44.00+359.3%+148.9%$814.91MN/A-17.4240Upcoming EarningsNews CoverageBCAXBicara TherapeuticsN/A$14.81+1.9%$32.43+119.0%N/A$807.49MN/A0.0032Analyst RevisionNews CoveragePositive NewsCMRXChimerix2.7367 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212,000.00-9.0990Analyst ForecastPositive NewsCDMOAvid Bioservices0.7931 of 5 stars$12.50+0.1%$12.25-2.0%+52.4%$799.18M$139.91M-5.23320High Trading VolumeDAWNDay One Biopharmaceuticals2.8256 of 5 stars$7.74flat$32.29+317.1%-54.9%$784.48M$131.16M-7.5160Upcoming EarningsNews CoveragePositive NewsOCSOculis2.8055 of 5 stars$17.86+5.1%$30.25+69.4%+46.1%$779.80M$980,000.00-9.252News CoveragePositive News Related Companies and Tools Related Companies Arcus Biosciences Alternatives Collegium Pharmaceutical Alternatives Avadel Pharmaceuticals Alternatives Vir Biotechnology Alternatives Anavex Life Sciences Alternatives Bicara Therapeutics Alternatives Chimerix Alternatives Avid Bioservices Alternatives Day One Biopharmaceuticals Alternatives Oculis Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:PRME) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prime Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Prime Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PRME Stock Free PRME Stock Alerts